Register Login

APREA THERAPEUTICS, INC. (APRE)

SymbolAPRE
NameAPREA THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address535 BOYLSTON STREET, BOSTON, Massachusetts, 02116, United States
Telephone+1 617 463-9385
Fax—
Email—
Websitehttps://www.aprea.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

Additional info from NASDAQ:
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).

2026-04-22 18:01

New Form S-3 - Aprea Therapeutics, Inc. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001104659-26-046900 <b>Size:</b> 524 KB

Read more
2026-04-21 14:15

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Read more
2026-04-20 07:30

New Form PRE 14A - Aprea Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001104659-26-045158 <b>Size:</b> 2 MB

Read more
2026-04-07 17:26

New Form SCHEDULE 13G - Aprea Therapeutics, Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0002050709-26-000012 <b>Size:</b> 81 KB

Read more
2026-04-06 12:00

Frazier Life Sciences Appoints Christian Schade as Senior Advisor

Read more
2026-04-01 20:15

Hamill John P. 🟢 acquired 62.0K shares (2 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.68 Transaction Date: Mar 31, 2026 | Filing ID: 038522

Read more
2026-04-01 20:15

Director Peters Richard 🟢 acquired 247.8K shares (2 derivative) of Aprea Therapeutics, Inc. (APRE) at $0.68 Transaction Date: Mar 31, 2026 | Filing ID: 038518

Read more
2026-04-01 12:45

(99% Neutral) APREA THERAPEUTICS, INC. (APRE) Announces Clinical Development Update

Read more
2026-03-30 12:01

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Read more
2026-03-20 07:03

New Form EFFECT - Aprea Therapeutics, Inc. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 9999999995-26-000871 <b>Size:</b> 1 KB

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06260514 Study of APR-1051 in Patients With Advanced Solid Tumors Phase1 Advanced Solid Tumor Recruiting 2024-06-13 2028-06-01 ClinicalTrials.gov
NCT04905914 Study Of ATRN-119 In Patients With Advanced Solid Tumors Phase1 Advanced Solid Tumor Active_Not_Recruiting 2023-01-09 2028-02-01 ClinicalTrials.gov
NCT04638309 APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplast… Phase1 MDS Terminated 2021-09-20 2022-04-25 ClinicalTrials.gov
NCT04419389 APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjec… Phase1 Non Hodgkin Lymphoma Terminated 2021-03-02 2021-08-24 ClinicalTrials.gov
NCT03588078 Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine Phase1 Myelodysplastic Syndrome With Gene Mutation Unknown 2018-09-15 2021-05-15 ClinicalTrials.gov
NCT03391050 A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BR… Phase1 Melanoma Terminated 2018-01-18 2018-08-08 ClinicalTrials.gov
NCT03072043 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant M… Phase1 Myelodysplastic Syndrome Completed 2017-05-18 2021-12-08 ClinicalTrials.gov
NCT00900614 Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prost… Phase1 Hematologic Neoplasms Completed 2009-05-01 2010-10-01 ClinicalTrials.gov
Total clinical trials: 8
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
APR-1051 DRUG Phase PHASE1 Advanced Solid Tumor RECRUITING NCT06260514
ATRN-119 DRUG Phase PHASE1 Advanced Solid Tumor ACTIVE_NOT_RECRUITING NCT04905914
APR-548 + Azacitidine DRUG Phase PHASE1 MDS TERMINATED NCT04638309
APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT DRUG Phase PHASE1 Non Hodgkin Lymphoma TERMINATED NCT04419389
APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT DRUG Phase PHASE1 Non Hodgkin Lymphoma TERMINATED NCT04419389
APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL DRUG Phase PHASE1 Non Hodgkin Lymphoma TERMINATED NCT04419389
APR-246 (eprenetapopt) + Acalabrutinib in CLL DRUG Phase PHASE1 Non Hodgkin Lymphoma TERMINATED NCT04419389
APR-246 (eprenetapopt) + Pembrolizumab DRUG Phase PHASE1 Bladder Cancer COMPLETED NCT04383938
Venetoclax DRUG Phase PHASE1 Myeloid Malignancy COMPLETED NCT04214860
APR-246 + azacitidine DRUG Phase PHASE3 MDS COMPLETED NCT03745716
Dabrafenib DRUG Phase PHASE1 Melanoma TERMINATED NCT03391050
Pegylated Liposomal Doxorubicin Hydrochloride (PLD) DRUG Phase PHASE2 High-grade Serous Ovarian Cancer COMPLETED NCT03268382
Azacitidine DRUG Phase PHASE1 Myeloid Malignancy COMPLETED NCT04214860
Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) DRUG Phase PHASE1 Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 COMPLETED NCT02098343
APR-246 DRUG Phase PHASE1 Myeloid Malignancy COMPLETED NCT04214860
Total products: 26